EU Approves Samsung Bioepis Infliximab Biosimilar

On May 30, the European Commission granted marketing authorization for FLIXABI,® an infliximab biosimilar developed by Samsung Bioepis, the joint venture between Biogen and Samsung Biologics.  See here for press coverage.

Download PDF